118 related articles for article (PubMed ID: 35288251)
1. Angiotensin-(1-7) reduces doxorubicin-induced aortic arch dysfunction in male and female juvenile Sprague Dawley rats through pleiotropic mechanisms.
Rahimi O; Melo AC; Westwood B; Grier RDM; Tallant EA; Gallagher PE
Peptides; 2022 Jun; 152():170784. PubMed ID: 35288251
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin-(1-7) reduces doxorubicin-induced cardiac dysfunction in male and female Sprague-Dawley rats through antioxidant mechanisms.
Rahimi O; Kirby J; Varagic J; Westwood B; Tallant EA; Gallagher PE
Am J Physiol Heart Circ Physiol; 2020 Apr; 318(4):H883-H894. PubMed ID: 32083974
[TBL] [Abstract][Full Text] [Related]
3. Chronic administration of angiotensin-(1-7) attenuates pressure-overload left ventricular hypertrophy and fibrosis in rats.
Wang LJ; He JG; Ma H; Cai YM; Liao XX; Zeng WT; Liu J; Wang LC
Di Yi Jun Yi Da Xue Xue Bao; 2005 May; 25(5):481-7. PubMed ID: 15897115
[TBL] [Abstract][Full Text] [Related]
4. Tranilast prevents doxorubicin-induced myocardial hypertrophy and angiotensin II synthesis in rats.
Zhan C; Bai N; Zheng M; Wang Y; Wang Y; Zhang L; Li J; Li G; Zhao H; Liu G; Lou Q; Yang W; Li T; Li L; Li W
Life Sci; 2021 Feb; 267():118984. PubMed ID: 33383049
[TBL] [Abstract][Full Text] [Related]
5. Role of aldosterone in angiotensin II-induced cardiac and aortic inflammation, fibrosis, and hypertrophy.
Neves MF; Amiri F; Virdis A; Diep QN; Schiffrin EL;
Can J Physiol Pharmacol; 2005 Nov; 83(11):999-1006. PubMed ID: 16391708
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin-(1-9) reverses experimental hypertension and cardiovascular damage by inhibition of the angiotensin converting enzyme/Ang II axis.
Ocaranza MP; Moya J; Barrientos V; Alzamora R; Hevia D; Morales C; Pinto M; Escudero N; García L; Novoa U; Ayala P; Díaz-Araya G; Godoy I; Chiong M; Lavandero S; Jalil JE; Michea L
J Hypertens; 2014 Apr; 32(4):771-83. PubMed ID: 24463937
[TBL] [Abstract][Full Text] [Related]
7. High glucose concentration augments angiotensin II mediated contraction via AT1 receptors in rat thoracic aorta.
Arun KH; Kaul CL; Ramarao P
Pharmacol Res; 2004 Dec; 50(6):561-8. PubMed ID: 15501693
[TBL] [Abstract][Full Text] [Related]
8. PPAR gamma agonists partially restores hyperglycemia induced aggravation of vascular dysfunction to angiotensin II in thoracic aorta isolated from rats with insulin resistance.
Gaikwad AB; Viswanad B; Ramarao P
Pharmacol Res; 2007 May; 55(5):400-7. PubMed ID: 17369046
[TBL] [Abstract][Full Text] [Related]
9. Puerarin protects against endothelial dysfunction and end-organ damage in Ang II-induced hypertension.
Li X; Lin Y; Zhou H; Li Y; Wang A; Wang H; Zhou MS
Clin Exp Hypertens; 2017; 39(1):58-64. PubMed ID: 28060542
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin Type 2 and Mas Receptor Activation Prevents Myocardial Fibrosis and Hypertrophy through the Reduction of Inflammatory Cell Infiltration and Local Sympathetic Activity in Angiotensin II-Dependent Hypertension.
Castoldi G; Carletti R; Ippolito S; Stella A; Zerbini G; Pelucchi S; Zatti G; di Gioia CRT
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948475
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin-(1-7) attenuates angiotensin II-induced cardiac hypertrophy via a Sirt3-dependent mechanism.
Guo L; Yin A; Zhang Q; Zhong T; O'Rourke ST; Sun C
Am J Physiol Heart Circ Physiol; 2017 May; 312(5):H980-H991. PubMed ID: 28411231
[TBL] [Abstract][Full Text] [Related]
12. Cardioprotection Generated by Aerobic Exercise Training is Not Related to the Proliferation of Cardiomyocytes and Angiotensin-(1-7) Levels in the Hearts of Rats with Supravalvar Aortic Stenosis.
Mota GAF; de Souza SLB; da Silva VL; Gatto M; de Campos DHS; Sant'Ana PG; Vileigas DF; Padovani CR; Casarini DE; de Oliveira EM; Bazan SGZ; Fernandes T; Sugizaki MM; Gomes ERM; Cicogna AC
Cell Physiol Biochem; 2020 Jul; 54(4):719-735. PubMed ID: 32730701
[TBL] [Abstract][Full Text] [Related]
13. The influence of angiotensin II-induced increase in aortic wall mass on compliance in rats in vivo.
Brouwers-Ceiler DL; Nelissen-Vrancken HJ; Smits JF; De Mey JG
Cardiovasc Res; 1997 Feb; 33(2):478-84. PubMed ID: 9074713
[TBL] [Abstract][Full Text] [Related]
14. Effect of lysyl oxidase inhibition on angiotensin II-induced arterial hypertension, remodeling, and stiffness.
Eberson LS; Sanchez PA; Majeed BA; Tawinwung S; Secomb TW; Larson DF
PLoS One; 2015; 10(4):e0124013. PubMed ID: 25875748
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin II-induced arterial thickening, fibrosis and stiffening involves elevated arginase function.
Bhatta A; Yao L; Toque HA; Shatanawi A; Xu Z; Caldwell RB; Caldwell RW
PLoS One; 2015; 10(3):e0121727. PubMed ID: 25807386
[TBL] [Abstract][Full Text] [Related]
16. Vascular but not cardiac remodeling is associated with superoxide production in angiotensin II hypertension.
Zhou MS; Jaimes EA; Raij L
J Hypertens; 2005 Sep; 23(9):1737-43. PubMed ID: 16093920
[TBL] [Abstract][Full Text] [Related]
17. Role of α1D -adrenoceptors in vascular wall hypertrophy during angiotensin II-induced hypertension.
Gallardo-Ortíz IA; Rodríguez-Hernández SN; López-Guerrero JJ; Del Valle-Mondragón L; López-Sánchez P; Touyz RM; Villalobos-Molina R
Auton Autacoid Pharmacol; 2015 Sep; 35(3):17-31. PubMed ID: 26845248
[TBL] [Abstract][Full Text] [Related]
18. Co-administration of resveratrol with doxorubicin in young mice attenuates detrimental late-occurring cardiovascular changes.
Matsumura N; Zordoky BN; Robertson IM; Hamza SM; Parajuli N; Soltys CM; Beker DL; Grant MK; Razzoli M; Bartolomucci A; Dyck JRB
Cardiovasc Res; 2018 Aug; 114(10):1350-1359. PubMed ID: 29566148
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin induces arterial stiffness: A comprehensive in vivo and ex vivo evaluation of vascular toxicity in mice.
Bosman M; Favere K; Neutel CHG; Jacobs G; De Meyer GRY; Martinet W; Van Craenenbroeck EM; Guns PDF
Toxicol Lett; 2021 Aug; 346():23-33. PubMed ID: 33895255
[TBL] [Abstract][Full Text] [Related]
20. Characterization of Angiotensin-(1-7) effects on the cardiovascular system in an experimental model of type-1 diabetes.
Yousif MH; Dhaunsi GS; Makki BM; Qabazard BA; Akhtar S; Benter IF
Pharmacol Res; 2012 Sep; 66(3):269-75. PubMed ID: 22580236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
